

FINANCIAL TEAR SHEET

Corporate Profile

AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1, we plan to develop AVXS-101 to treat additional SMA types and develop other novel treatments for rare neurological genetic diseases.

Stock Information

AVXS (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	\$97.33
Change (%)	▼ 1.43 (1.45%)
Volume	131,389
52 Week High	\$108.27
52 Week Low	\$44.68
Market Cap	\$3,157,991,042
Rolling EPS	-5.58
PE Ratio	0
Shares Outstanding	31,976,418
Data as of 11/17/17 12:21 p.m. ET	



Recent Headlines

11/09/17

[AveXis Reports Third Quarter 2017 Financial and Operating Results](#)

11/02/17

[AveXis to Report Third Quarter 2017 Financial and Operating Results](#)

11/01/17

[AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
11/13/17	SC 13D/A
11/09/17	10-Q
11/09/17	8-K
11/03/17	4

Primary IR Contact

Vice President, Investor Relations and Corporate Communications

Jim Goff

Phone: (650) 862-4134

E-mail: jgoff@avexis.com

Data provided by Nasdaq. Minimum 15 minutes delayed.